ProfileGDS5678 / 1451320_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 24% 24% 25% 25% 24% 55% 25% 24% 25% 32% 25% 24% 24% 29% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5945924
GSM967853U87-EV human glioblastoma xenograft - Control 22.5589824
GSM967854U87-EV human glioblastoma xenograft - Control 32.5754425
GSM967855U87-EV human glioblastoma xenograft - Control 42.523125
GSM967856U87-EV human glioblastoma xenograft - Control 52.5156124
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4848655
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6209225
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.5504724
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5462125
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7201832
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5595625
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5402624
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5576524
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6525229